URL has been copied successfully!
ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.
The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.
Each team has a deadline of starting clinical trials by year three of the program, although some may start much sooner.
Please follow us:
